MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions involving NTRK1, NTRK2, and NTRK3. The TRK inhibitor Vitrakvi® (larotrectinib) was recently FDA-approved for treatment of adult and pediatric patients with solid tumors that have a NTRK gene fusion. NGS is the most comprehensive method to identify NTRK gene fusions, particularly in cases with minimal available tissue. MLabs performs these panels using as little as <1mm²  tissue with a 4% QNS rate. For more information about our tissue requirements for NGS testing visit Less Tissue More Results.  

MLabs NGS panels not only detect NTRK gene fusions, but include many other standard of care and emerging biomarkers in solid tumors. A complete list of genes assessed for mutations, amplifications and fusions is listed below.

Hotspot Mutation Detection	Amplification	Selected Fusion Detection
AKT1	IDH2	ALK	FGFR3	ALK	RAF1
ALK	JAK1	AR	FGFR4	RET	ERG
AR	JAK2	BRAF	KIT	ROS1	ETV1
BRAF	JAK3	CCND1	KRAS	NTRK1	ETV4
CDK4	KIT	CDK4	MET	NTRK2	ETV5
CTNNB1	KRAS	CDK6	MYC	NTRK3	AXL
DDR2	MAP2K1	EGFR	MYCN	FGFR1	EGFRvIII
EGFR	MAP2K2	ERBB2 (HER2)	PDGFRA	FGFR2	ERBB2 (HER2)
ERBB2 (HER2)	MET	FGFR1	PIK3CA	FGFR3	PDGFRA
ERBB3	MTOR	FGFR2		MET	PPARG
ERBB4	NRAS			BRAF
ESR1	PDGFRA
FGFR2	PIK3CA
FGFR3	RAF1
GNA11	RET
GNAQ	ROS1
HRAS	SMO
IDH1